Robert Wessman: the case for patent reform

23 August 2023
biologic_biosimilar_lab_large

An Expert View from Róbert Wessman, founder and chairman of Icelandic biosimilars company Alvotech (Nasdaq: ALVO) and investment fund Aztiq.

Making the case for change

The purpose of an appropriately balanced intellectual property (IP) system is to incentivize innovation and increase economic growth. Unfortunately, some pharma companies spend significant resources on manipulating the IP enforcement system to improperly extend expiring monopolies. They exploit unintended or unforeseen ambiguities in the law to crush competition rather than to protect innovation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars